Home Blog Page 2068

LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities

  • Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market.
  • The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported by joint marketing based on deep ADC expertise.

SEOUL, South Korea, Oct. 30, 2025 /PRNewswire/ — LOTTE BIOLOGICS (CEO James Park) and SK pharmteco (CEO Joerg Ahlgrimm) announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market.

Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol Shin, CSO, LOTTE BIOLOGICS; James Park, CEO, LOTTE BIOLOGICS; Joerg Ahlgrimm, CEO, SK pharmteco; Andy Fenny, CCO, SK pharmteco; Olivia Boyce, Global Head of Proposals, SK pharmteco; Shiuk Lee, CSO, SK pharmteco; Steve Barr, Head of Small Molecule, SK pharmteco.
Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol Shin, CSO, LOTTE BIOLOGICS; James Park, CEO, LOTTE BIOLOGICS; Joerg Ahlgrimm, CEO, SK pharmteco; Andy Fenny, CCO, SK pharmteco; Olivia Boyce, Global Head of Proposals, SK pharmteco; Shiuk Lee, CSO, SK pharmteco; Steve Barr, Head of Small Molecule, SK pharmteco.

Through this collaboration, the two companies will jointly investigate providing integrated, one-stop CDMO services to global clients, offering differentiated ADC solutions that span from development to commercial manufacturing.

LOTTE BIOLOGICS will utilize its cGMP manufacturing capabilities and global quality competitiveness at its Syracuse Bio Campus in the U.S. to deliver high-quality bioconjugation and drug substance manufacturing services.

Meanwhile, SK pharmteco will be responsible for linker–payload development and manufacturing within the chemical-synthesis portion of the process, complementing LOTTE BIOLOGICS’ bioconjugation and drug-substance manufacturing.

By combining technical expertise and global networks, the companies aim to create a fully integrated CDMO platform that minimizes development-to-manufacturing gaps, offers customized solutions for clients, and strengthens competitiveness in the rapidly expanding ADC sector. 

They also plan to jointly pursue global marketing and client engagement to expand their customer base across key markets.

The partnership also aligns with the ongoing global trend toward supply chain reshoring, as each company possess advanced manufacturing infrastructures in both the U.S. and Europe. 

James Park, CEO of LOTTE BIOLOGICS, stated, “This collaboration marks a meaningful milestone, as two leading Korean biopharma join forces on the global stage. By combining our strengths in advanced modalities such as ADCs, we will reinforce Korea’s biopharmaceutical leadership and accelerate our growth in the global market.”

Joerg Ahlgrimm, CEO of SK pharmteco, added, “This strategic partnership will supercharge the development of next-generation therapeutics, positioning both companies to deliver significantly greater value and accelerate the delivery of innovative new medicines to patients around the world.”

About LOTTE BIOLOGICS

Headquartered in Seoul, South Korea, LOTTE BIOLOGICS was founded in 2022 with a mission to deliver therapies that contribute to a healthier world. At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) conjugation services. With over $100 million invested in ADC modalities, including both drug substance and conjugation capabilities on-site, we offer a seamless, end-to-end service from drug substance manufacturing to conjugation. Looking ahead, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2027.

About SK pharmteco

SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.

Global Times: China-South Korea Literature Salon held at Korean Cultural Center in Beijing

BEIJING, Oct. 30, 2025 /PRNewswire/ — To thoroughly study, promote, and implement Xi Jinping Thought on Culture and to advance mutual learning between Chinese and foreign civilizations, the Global Times “Reading Through the Seasons” China-South Korea Literature Salon was held on Wednesday at the Korean Cultural Center, China. The event aimed to build a new platform for cultural exchange between China and South Korea through literary dialogue.

Jointly presented by the Global Times, the Korean Cultural Center, and the World Sinology Center at Beijing Language and Culture University (BLCU), the event brought together renowned writers and translators from both countries to explore the charm of literature and listen to the symphony of East Asian literature through bilingual verses infused with the fragrance of ink. It was also a continuation of the Global Times’ “Reading Through the Seasons” series of events.

Bai Long, deputy editor-in-chief of the Global Times, said in his opening speech that he hopes this event will deepen cultural exchanges between the two countries, foster closer dialogue and more frequent mutual translations among writers, scholars, and publishers, and inspire the younger generation to explore through reading and creation the common challenges faced by humanity. 

Bai noted that the Global Times has long been a witness, recorder, and promoter of literary dialogue and cultural exchange between China and South Korea.

Kim Jin-gon, director of the Korean Cultural Center, China, told the Global Times that South Korea and China are close in geography, connected in culture, and bound by deep people-to-people ties – precious neighbors inseparably linked to each other.

Xu Baofeng, director of the World Sinology Center at BLCU, said young people represent the future of both China and South Korea, and the future of Asia. “We hope that through events like today’s literary salon, dialogue between Chinese and South Korean literature will spark new inspiration and meaningful exchanges of ideas.”

During the salon, Kim Tae-sung, a South Korean translator and winner of the 10th Special Book Awards of China; Dong Xi, president of the Guangxi Writers Association and professor at Guangxi Minzu University; South Korean writer Lee Jee; and Cui Youxue, associate professor at the School of Chinese Ethnic Minority Languages and Literature, Minzu University of China, shared their journey on the literary exchanges between China and South Korea. 

At the following roundtable discussion, Yin Hanchao, deputy director of the Chinese Studies Center of the National Library of China, said that China and South Korea both belong to the Confucian cultural sphere, therefore share common values and ways of thinking in this regard.

The speakers at the roundtable elaborated on topics such as the locality and globality of contemporary literature from both countries in the context of globalization.

In a major move of advocating for reading and literary exchanges, student representatives from China and South Korea and the hosts jointly launched a reading initiative, calling on youths from the two countries to use books as a bridge and transform literary wisdom into a driving force for action.

Since 2023, the Global Times has hosted five offline events featuring reading and literature.

Bai Long, deputy editor-in-chief of the Global Times: 

From the records of ancient Korean envoys documenting the customs and landscapes of China to the wide circulation of contemporary Chinese and South Korean literary works, books have always served as vital vessels of civilization, bonds of emotion between the two peoples, and witnesses to shared history and changing times. The vibrancy of economic and trade exchanges, coupled with the resonance between civilizations, together paints a colorful picture of the bilateral relationship and provides fertile ground for literary exchanges between China and South Korea.

Kim Jin-gon, director of the Korean Cultural Center, China:

Personally, I believe that literature is the essence of culture. When it is translated into other languages, it becomes the most accessible and profound medium for mutual understanding. I hope that today’s literary salon will serve as an opportunity to further expand exchanges and cooperation between South Korea and China in the fields of translation and publishing, deepening mutual understanding and friendship between our peoples.

Xu Baofeng, director of the World Sinology Center at BLCU:

China and South Korea share deep bonds between their peoples and a natural affinity in culture and literature, giving them unique advantages in fostering people-to-people exchanges. The World Sinology Center at BLCU will continue to work with all partners, using language as a medium and culture as a bridge, to deepen academic cooperation. Together, we hope to help Chinese and South Korean literature resonate in harmony through mutual learning, and to steer the vessel of literary friendship between our two countries across mountains and seas toward a brighter shore.

Kim Tae-sung, South Korean translator, winner of the 10th Special Book Awards of China:

South Korea is one of the countries that has absorbed the most Chinese cultural content… If you go right now to a large bookstore in Seoul, how many books related to China can you find? At least more than 1,000. Books related to Lu Xun alone exceed 100. This is probably because, as the nearest neighboring country, there is an urgent need to understand and gain knowledge about China.

Dong Xi, president of the Guangxi Writers Association, professor at Guangxi Minzu University:

Chinese and South Korean literature use the narrative shell of “transformation” to convey distinct themes. Writers from different eras and countries have all employed the motif of “transformation” to express their unique experiences and themes. Every form of “transformation” exists to achieve a sense of normalcy.

Lee Jee, South Korean writer:

Just as flowers, though sharing the same roots, blooming in different colors due to variations in soil and climate, South Korean and Chinese literature have become richer through their differences. If the globalization of literature has been advanced through translation, then the current intergenerational shift is creating another turning point. Readership has undergone more rapid and radical changes in the past decade than those witnessed over the previous hundred years.

Cui Youxue, associate professor at School of Chinese Ethnic Minority Languages and Literature, Minzu University of China:

I would like to share with you my understanding of the poetic nature of Han Kang’s literature… The poetic quality of Han’s works stems from her steadfast commitment to writing poetry and her continuous effort to infuse poetic elements into fiction.

Yin Hanchao, deputy director of the Chinese Studies Center of the National Library of China:

China and South Korea both belong to the Confucian cultural sphere, therefore share common values and ways of thinking in this regard. Chinese works To Live, Chronicle of a Blood Merchant and South Korea’s Stingray all portray fathers as responsible and devoted figures. Such universal cultural symbols resonate deeply across regions and help people empathize with one another.

Roundtable discussions

Chinese and South Korean guests communicated on reading and literary exchanges between the two countries during a roundtable session at the event.

Reading begins with our neighbors, said Dong Xi. Many of our literature courses today take a long detour before paying attention to East Asian authors. Yet when we read South Korean works, there’s a sense of familiarity: We share the same roots, our cultures are similar, and the issues we face are often alike. The most important aspect of universality lies in humanity: If a work embodies genuine human emotions, it will move readers all over the world.

Yin Hanchao said that, from a translator’s perspective, Chinese translators were already thinking about how to better translate Chinese works for the world more than a century ago. For a nation to have the vision and confidence to present its own works to the world for others to appreciate, judge, or even critique, that in itself is a true expression of cultural confidence.

In Kim Tae-sung’s view, language is the vessel of culture, and the only means to digest it is through reading. He said Chinese author Liu Zhenyun’s novels possess a kind of narrative humor, while Dong Xi’s works are remarkable for their skillful use of metaphor. Both are distinctive qualities of Chinese writers. South Korean literature should engage in deeper exchanges with Chinese literature, he said.

As a novelist, Lee Jee said we should foster closer literary exchanges through fiction. Only works written with tears and blood can evoke true empathy among people around the world – that’s how they travel beyond borders.

According to Cui Youxue, for translators, all literary history is essentially a history of translation. He believes translators have made great contributions to the development of national literatures, languages, and even to the formation of nations themselves. Reading, in turn, is a form of spiritual communication: A good novel can profoundly move the heart, and those who read feel spiritually fulfilled every day.

 

SoftwareOne Signs Strategic Collaboration Agreement with AWS to Accelerate Gen AI Innovation Across APAC


SINGAPORE – Media OutReach Newswire – 30 October 2025 – SoftwareOne, a global leader in cloud and software services, today announced a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to accelerate digital transformation, cloud adoption, and generative artificial intelligence (Gen AI) innovation across the Asia-Pacific (APAC) region.

SoftwareOne Signs Strategic Collaboration Agreement with AWS
SoftwareOne Signs Strategic Collaboration Agreement with AWS

Under the multi-year agreement, SoftwareOne will enhance its AWS capabilities to support customers in Australia-New Zealand (ANZ), Southeast Asia, Greater China Region (GCR), and India. The collaboration focuses on four strategic areas: migration and modernization, data and Gen AI, launching entirely new solutions on AWS (greenfield deployments), and AWS Marketplace enablement. SoftwareOne will continue to invest in obtaining AWS certifications, ensuring SoftwareOne employees are equipped with the latest AWS expertise to support customers across the APAC region.

“This agreement marks a pivotal step in our mission to empower organizations across APAC to accelerate digital transformation using Gen AI,” said Varun Paliwal, President APAC and Middle East of SoftwareOne. “By combining SoftwareOne’s expertise with the comprehensive cloud services of AWS, we’re delivering tangible business outcomes and long-term value for our customers.”
“This collaboration with SoftwareOne demonstrates our joint focus on helping customers across APAC accelerate both cloud transformation and responsible generative AI adoption,” said Corrie Briscoe, Director of Partner Core, Asia Pacific & Japan, AWS. “By combining SoftwareOne’s deep regional expertise and trusted customer relationships with AWS’s breadth of services—including Amazon Bedrock—we’re creating practical pathways for organizations to modernize their operations, innovate with confidence, and scale solutions that drive measurable impact.”
SoftwareOne will develop and deploy a portfolio of Gen AI solutions powered by Amazon Bedrock, tailored to industries such as retail, manufacturing and financial services. To accelerate adoption, SoftwareOne will provide pre-built, AWS-validated solution templates and implementation packages, including AI assistants for specific industries and workloads, which are designed to help customers move from pilot to production faster. AWS will provide technical assistance and collaborate with SoftwareOne teams through its Generative AI Innovation Centre (GenAIIC) Partner Alliance, which SoftwareOne has joined, and which will provide access to expert-level training and delivery acceleration.
The AI Assistants that will be launched through SoftwareOne’s collaboration with AWS include:
  • Technician AI Assistant for factory troubleshooting and maintenance queries.
  • Insurance AI Assistant for personalized plan recommendations and sentiment analysis.
  • HR Policy Assistant to automate employee inquiries and HR ticket creation.
  • Product Assistant for intelligent product search, promotion discovery, and order management.
As part of the collaboration, SoftwareOne will help customers migrate to AWS through its Rapid Migration Offer, deploy a new SoftwareOne AWS Landing Zone with built-in cloud security and governance, and will list its solutions in AWS Marketplace to streamline procurement. SoftwareOne will also invest in dedicated AWS-focused sales and marketing headcount across APAC to support customers throughout their cloud journey.

This collaboration will enhance SoftwareOne’s vision of delivering flexibility, innovation, and business value for customers across industries. To explore how SoftwareOne can accelerate your cloud journey with AWS, visit: softwareone.com

Hashtag: #SoftwareOne #AWS #GenAI

The issuer is solely responsible for the content of this announcement.

SoftwareOne

SoftwareOne and Crayon have joined forces to become a global, AI-powered software and cloud solutions provider. With a presence in over 70 countries and a team of around 13,000 professionals, the combined organization brings together global scale and local expertise to help clients reduce costs, accelerate growth, and navigate complex IT environments with confidence. Leveraging deep capabilities in cloud, software, data, and AI, the company empowers organizations to modernize, innovate, and unlock the full value of their technology investments.
Exchange and Euronext Oslo Børs under the ticker symbol SWON. Visit us at

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection

SHANGHAI, Oct. 30, 2025 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. Building on ArkBio’s previous experience and knowledge in development of RSV therapeutics, this milestone marks a major step forward in RSV prevention and enriches the company’s innovative anti-RSV drug portfolio.

The multicenter, randomized, double-blind, placebo-controlled, dose-escalation phase II study will assess the safety, tolerability, and pharmacokinetics of AK0610 Injection in healthy infants in China. The study will be conducted at five centers nationwide, jointly led by Professor Xin Ni of Beijing Children’s Hospital, Capital Medical University, and Professor Hanmin Liu of West China Second Hospital, Sichuan University.

RSV is a leading cause of acute lower respiratory tract infections (ALRTI) in children under 5 years of age worldwide. More than 80% of children become infected before their first birthday, and nearly all have been exposed at age two. Among those infected, approximately one-third may develop severe ALRTI, such as bronchiolitis or pneumonia. Infants under one year of age, particularly preterm infants, are at greatest risk of developing serious RSV-related complications, often requiring hospitalization. Given China’s large infant population and persistent RSV prevalence, the country faces a significant healthcare burden, underscoring the urgent need for novel, long-acting preventive interventions.

AK0610 is a monoclonal antibody targeting the pre-fusion F protein of RSV. It was isolated from a convalescent infant and subsequently engineered to enhance durability. Distinguished by its unique binding epitope and mechanism of action, AK0610 maintains robust neutralizing activity across RSV variants, especially RSV B strains. Preclinical data demonstrated strong antiviral activity with an excellent safety profile. In the completed phase I trial in healthy adults, AK0610 was safe, well-tolerated, and exhibited favorable pharmacokinetic properties. With an extended half-life, a single dose may provide season-long protection, positioning AK0610 as a promising new-generation long-acting antibody for prophylaxis of RSV infection in infants.

Professor Xin Ni stated:
“RSV remains the leading viral cause of hospitalization among infants and young children in China, especially those under one year of age, placing a heavy burden on families and the healthcare system. There is an urgent need for domestically developed innovative preventive antibodies capable of offering durable protection throughout the RSV season. The initiation of AK0610’s Phase II clinical study is an important milestone in advancing such preventive strategies. Evaluating its safety and pharmacokinetics in healthy infants is an essential step towards developing this antibody for China as well as the global vast infant population. We are optimistic that the study will pave the way for this promising drug candidate to safeguard the healthy growth of infants globally.”

Professor Hanmin Liu added:
“AK0610 is a fully human monoclonal antibody with a unique mechanism of action and excellent clinical potential. Its potent, highly specific neutralizing activity and extended half-life make it a strong candidate for RSV prevention. The rigorously designed phase II study will provide important data on its safety and pharmacokinetic characteristics in infants, establishing a solid foundation for future pivotal trials. Together with participating centers across the nation, we are committed to conducting this clinical trial with scientific rigor with a goal to reduce the burden of RSV-related diseases among infants.”

About ArkBio

ArkBio is a global biotech company focused on developing innovative therapeutics for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house R&D efforts and external collaboration. Key drug assets include ziresovir (AK0529), the first direct-acting RSV antiviral with positive pivotal phase III results, and AK0901, an ADHD therapeutic drug, both of which have filed NDA to China CDE for market approval.

ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions.

For more information, please visit: www.arkbiosciences.com 

Investor Inquiries: IR@arkbiosciences.com 

Jenscare released its multi-product portfolio’s, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

BEIJING, Oct. 30, 2025 /PRNewswire/ — Jenscare Scientific Co., Ltd. (“Jenscare” or the “Company”) (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes and challenging cases of JensClip and Ken-Valve, a proprietary TMVr system and TAVR (AR) system respectively, representing the Company’s diversified and high-potential multi-product portfolio, at TCT 2025 in the U.S..

6-Month Follow-up Results of LuX-Valve Plus TRINITY Study
-Released by Prof. Thomas Modine, CHU de Bordeaux-Haut-Leveque, France

TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid regurgitation and high surgical risk. The study enrolled 161 patients from 20 centers around the world, among which, 18 centers were from France, Germany, Spain, Denmark, and the UK.

The average age of the patients (FAS + Roll-in group) is about 77 years old with an average STS score of 10.24%. 91.93% of the patients has atrial fibrillation, 32.92% has left heart surgery/intervention, 26.71% has pacemaker/ICD implanted. Patients are combined with multi other comorbidities, which formed a poor baseline and increased the risks of surgical treatment or difficulties of other interventional therapies. Over 75% of enrollments utilized valve sizes between 55mm and 70mm. The results show that the device success rate is about 97%, and the average device operation time is around 41.60 minutes with the shortest time being 11 minutes.

The safety indicators show that the overall CEC-adjudicated composite events rate at 6-month of FAS + Roll-in group is 19.9%. Cardiovascular mortality is 3.7%, the incidence of strokes is 0.6%, new onset renal failure is 1.2%, non-selective tricuspid valve surgery/intervention post procedure is 2.5%, major cardiac structural complications is 3.1%, severe bleeding (including fatal, life-threatening and extensive bleeding as defined by MVARC) is 5.0%, new pacemaker implantation due to AVB is only 8.7% (no change compared to that at 30 days). No events prevailed in myocardial infarction, major access site and vascular complications, and device-related pulmonary embolism.

The efficacy indicators show that the tricuspid regurgitation (TR) grade, NYHA classification, and QoL improved significantly at 6 months. 94.4% of the patients show no above moderate TR. 90.9% of them show postoperative NYHA class I/II. KCCQ score increased by around 19 pts on average. 6MWD increased by 39 meters on average.

Professor Thomas Modine concluded that LuX-Valve Plus TTVR system is an innovative device indicated for high-surgical risk patients with severe TR and demonstrates several advantages. First, it has radial-force independent anchoring mechanism, which is designed particularly for TV. Second, it indicates low demands on imaging quality, which is expected to significantly reduce device time. Third, it provides large size options, which enables wide applicability on large TV anatomies. The 6-month clinical outcomes of TRINITY Trial demonstrate good safety and performances, with improvements in quality of life and low rate of composite adverse events. The wide application on large anatomy patients provides encouraging treatment options for severe TR patients, while current therapies are limited. Further follow-ups of TRINITY trial and clinical evidence worldwide using LuX-Valve Plus system are underway. Currently, the U.S. FDA IDE-EFS for LuX-Valve Plus has completed full enrollment with excellent safety and efficacy outcomes.

Meanwhile, evidence supporting the efficacy and safety of the transjugular approach for LuX-Valve Plus was also presented. The advantages of the transjugular approach include low incidence of access site bleeding complications, reflecting high safety profile; shorter device operation time, demonstrating good procedural efficiency; and a low screening failure rate due to the anatomical structure of the jugular vein. Current data from the TRAVEL II and TRINITY studies show bleeding complication rates of 0% and 1.8% respectively, representing outstanding clinical outcomes.

One-Year Follow-Up Results of JensClip
-Released by Prof. Vinicius Esteves, University Hospitals in Cleveland, U.S.

The study of JensClip TMVr system is a prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of JensClip in application on patients with symptomatic degenerative mitral regurgitation (DMR) at high surgical risk. The study enrolled 114 patients from 18 centers in China.

The average age of the patients is about 71 years old with an average STS score of 7.65%. 63.2% of the patients has hypertension history, 41.2% has coronary artery disease, 30.7% has atrial fibrillation, and 91.2% has pre-operative NYHA class III/IV. The results show that the device success rate at 30 days is about 95%, and the average device operation time is around 67.53 minutes.

The safety indicators show that the all-cause mortality rate is 1.8%. The incidence of unplanned mitral valve intervention/surgery is 5.3%, and that of stroke is 1.8%. The incidence of renal failure, myocardium infarction, major bleeding, device releasing/locking failure, and clip related hemolysis are all 0.9%. No events prevailed in SLDA and device related air embolism.

The efficacy indicators show that the mitral regurgitation (MR) grade, NYHA classification, and QoL improved continuously at 1 year. 96.29% of the patients show no above moderate MR. 93.46% of them show postoperative NYHA class I/II. KCCQ score increased by around 20 pts on average. 6MWD increased by around 82m from the baseline.

Professor Vinicius Esteves concluded that JensClip is an innovative device intended for severe DMR, providing easy and reliable operation with unique designing features like continuous-adjustable locking system and independent grasping technique. The 1-year clinical outcomes demonstrated procedural safety and durable MR reduction.

One-Year Follow-Up Results of Ken-Valve
-Released by Prof. Anson Cheung, St. Paul’s Hospital, Canada

The study of Ken-Valve TAVR system is a prospective, multicenter, single-arm clinical trial, which primarily evaluates the safety and efficacy of Ken-Valve in application on patients with symptomatic aortic regurgitation (or combined with aortic stenosis) at high surgical risk. The study enrolled 142 patients from 15 centers in China.

The average age of the patients is about 70 years old with an average STS score of 5.87%. 61.97% of the patients has moderate to severe frailty, 71.83% has hypertension history, 42.96% has coronary artery disease, 48.59% has peripheral vascular disease, 51.41% has prior surgical history, and 99.30% has pre-operative NYHA class III/IV. The results show that the device success rate is about 97%, and the average device operation time is around 8.70 minutes.

The safety indicators show that all-cause mortality is 5.63%. The incidence of severe bleeding is 4.23%, and conversion to surgery is 1.41%. Both the incidence rate of stroke and valve migration is 2.11%. Both the incidence of acute renal dysfunction and needed for cardiopulmonary mechanical assistance is 0.7%. No events prevailed in coronary artery obstruction, thrombosis, and cardiac tamponade.

The efficacy indicators show that the aortic regurgitation (AR) reduction, NYHA classification, and QoL improved continuously at 1 year. 94.7% of the patients show no above moderate paravalvular leakage. 96.2% of them show postoperative NYHA class I/II. EQ-5D score increased by around 19 pts on average. The function and performance of Ken-Valve remain favorable with stable EOA and transvalvular gradient at 1 year.

Professor Anson Cheung concluded that Ken-Valve TAVR system is an innovative device indicated for high-surgical risk patients with severe AR or predominantly regurgitant mixed with aortic valve stenosis with several advantages. Ken-Valve has integrated clamping and radial force anchoring mechanism which can provide reliable anchoring force. It has a leak-proof ring which is expected to minimize PVL post-implantation. It provides large size options which enables wide applicability on large aortic valve anatomies. The deflectable delivery system allows better co-axiality and alignment when treating complex anatomies like horizontal heart. The 1-year clinical outcomes of the Ken-Valve Pivotal Trial demonstrated good safety and performances, with improvements in quality of life, stable EOA and transvalvular gradient, and low rate of composite adverse events. The wide application on large anatomy patients provides encouraging treatment options for severe AR patients while current therapies are limited.

About LuX-Valve Plus

LuX-Valve Plus, the proprietary TTVR system, is designed for patients with severe tricuspid TR and high surgical risk. LuX-Valve Plus breaks through multiple technical difficulties in tricuspid valve interventional therapy. With the design of innovative “interventricular septum anchoring” and “leakproof self-adaptive braided ring”, which enables non-radial anchoring of the valve implant and tend to effectively prevent AV block. LuX-Valve series product is designated by the FDA as a breakthrough device, is enrolled in the Total Product Life Cycle Advisory Program (TAP) pilot of the FDA and is selected for the Expert Panel Scientific Advice Pilot by the EMA. As of the latest update, close to 1000 implantation cases have been completed worldwide with the LuX-Valve series products, and the longest follow-up record has been over 6 years.

About JensClip

JensClip, the proprietary TMVr system, features an innovative self-locking design, which is expected to effectively improve mitral regurgitation and reduce leaflet tension. The valve clip allows for flexible shape adjustments, which is expected to enhance procedural safety and improve intraoperative maneuverability. Furthermore, its one-piece release mechanism is designed to minimize potential mis-operation risks associated with staged detachment, effectively reducing device operation time.

About Ken-Valve

Ken-Valve, the proprietary first-generation TAVR system, is designed for the treatment of patients with severe AR or combined with AS. Its innovative design accommodates a wide range of complex anatomies, significantly improving procedural safety and flexibility while reducing device operation time. It offers six annulus sizes – 23mm, 25mm, 27mm, 29mm, 31mm and 33mm. Its unique innovative design and applicability to complex anatomical challenges, such as large annulus and horizontal heart, can address the treatment needs of patients with large annulus for whom treatment options are relatively limited.

About Jenscare

Jenscare is an innovative medical device company, established in 2011. The Company has achieved a diversified and high-potential product portfolio of interventional treatment solutions for different types of structural heart diseases, including tricuspid valve disease, mitral valve disease, aortic valve disease and so on. The Company is continuing to expand its global business layout, enhancing product influence and clinical application scale, thereby laying a solid foundation for sustained high-speed growth. 

Ubiqconn Technology Takes the Spotlight at APSCC 2025, Driving Global Collaboration in SATCOM-Ready Mobility

Ubiquitous Connectivity Unites Global Satellite Leaders to Shape the Future of the Space Industry

TAIPEI, Oct. 30, 2025 /PRNewswire/ — Ubiqconn Technology, a leading provider of SATCOM-ready mobility and rugged computing solutions, will take center stage at the APSCC 2025 Conference (Asia-Pacific Space Community Council Conference 2025), held November 4–6 at the Taipei Marriott Hotel. Under the theme “Ubiquitous Connectivity – Powering the Last Mile with SATCOM-Ready Mobility,” Ubiqconn will spotlight its innovative approach to integrating terrestrial communications, mobile computing, and satellite applications. Through this showcase, the company aims to bridge global space communication ecosystems and reaffirm its mission to enable seamless, borderless connectivity across industries and regions.

Ubiqconn Technology Takes the Spotlight at APSCC 2025, Driving Global Collaboration in SATCOM-Ready Mobility
Ubiqconn Technology Takes the Spotlight at APSCC 2025, Driving Global Collaboration in SATCOM-Ready Mobility

As a key co-organizing partner of APSCC 2025, Ubiqconn Technology brings deep industry expertise and facilitates cross-sector collaboration to strengthen Taiwan’s role as a strategic player in the Asia-Pacific space economy. The three-day conference gathers experts from over 25 countries, covering GEO, MEO, and LEO multi-orbit collaboration, AI-driven satellite operations, 5G NTN integration, and sustainable space development, marking Taiwan’s official entry into the global satellite network.

With the vision of “Ubiquitous Connectivity,” Ubiqconn Technology continues to build an integrated ecosystem that connects ground and orbital networks. Its product portfolio spans satellite gateways, SATCOM antennas, in-vehicle computers, rugged tablets, and unmanned ground control systems, enabling reliable communications across maritime, logistics, public safety, mining, and agricultural sectors.

“Ubiqconn Technology is committed to enabling ubiquitous connectivity that empowers industries to operate without boundaries,” said Paul Hsieh, CEO of Ubiqconn Technology. “By linking ground and space, we are shaping the future of resilient and intelligent communications for the Asia-Pacific region and beyond.”

Leveraging a robust foundation in electronics manufacturing and system integration, Ubiqconn Technology is fostering collaboration among industry, government, and academia to drive end-to-end vertical integration—from chip design and terrestrial communication modules to advanced space application platforms. Through its participation in APSCC 2025, Ubiqconn aims to strengthen global partnerships across the satellite value chain and reinforce its leadership in the Asia-Pacific space ecosystem.

About Ubiqconn Technology

Ubiqconn Technology is a leading provider of rugged mobile and satellite connectivity solutions, delivering value-added services across critical sectors including satellite communication, maritime, rugged smart mobility, and government. Guided by the vision of “Ubiquitous Connectivity,” Ubiqconn emphasizes user-centric thinking, agile go-to-market strategies, and engineering excellence to help clients solve real-world challenges and bring innovation to life.

For more information, please visit our website: www.ubiqconn.com.

IQAX and CargoNPay Partner to Launch AI-Driven eBL Shipping Instruction Solution

Collaboration sets a new benchmark for digital transformation in China’s freight industry.

HONG KONG, Oct. 30, 2025 /PRNewswire/ — IQAX, a global leader in digital trade intelligence technology, has entered a strategic partnership with CargoNPay, a premier logistics technology platform based in China. This collaboration integrates IQAX One intelligent trade ecosystem and its blockchain-based electronic Bill of Lading (eBL) solution with CargoNPay’s AI-powered document processing system, creating a seamless, secure end-to-end solution for freight forwarders across China.

At the core of the partnership is an industry-first AI-based B/L Shipping Instruction and blockchain-enabled electronic Bill of Lading (eBL) workflow. It is designed to automate, secure, and accelerate trade document processing.

Key features include:

1)    Automated Data Extraction: CargoNPay’s AI technology identifies, extracts, and verifies key data from customer documents to generate precise information required for eBL applications.

2)    Seamless Integration: Freight forwarders can transmit this data through CargoNPay’s platform to carriers connected to the IQAX network, enabling faster eBL initiation.

3)    Digital Issuance: IQAX eBL ensures the secure and efficient issuance of legally binding electronic bills of lading, digitizing the entire trade documentation process. 

This collaboration dramatically reduces manual data entry, minimizes human error, and shortens document turnaround times from days to just hours.

George Guo, CEO of IQAX, said, “We value CargoNPay’s industry-leading capabilities in AI-powered document recognition. The combination of technologies delivers unprecedented operational convenience for freight forwarders and advances the development of an international digital intelligence trade ecosystem. This aligns fully with our vision of empowering the logistics industry and creating enhanced value through strategic partnership.”

Edward  Ma, CEO of CargoNPay, added, “Partnering with IQAX has allowed us to realise the full potential of our AI technology in real-world logistics applications. By integrating IQAX’s trusted eBL services, we have achieved a fully closed-loop online service and established a digital hub that connects freight forwarders and carriers more effectively than ever.”

Beyond eBL functionality, CargoNPay users can now access the full range of IQAX One digital services, including real-time vessel scheduling, cargo tracking, inland transport monitoring, and electronic document submission, offering complete visibility and automation across the logistics value chain.

The AI-powered B/L creation and eBL issuance service is now available to CargoNPay users.

About IQAX 

IQAX is a digital trade intelligence company powering critical decisions across global supply chains. We help businesses act faster, build resilience and become more sustainable by solving their most complex challenges. From IQAX eBL to digital twins, our solutions embed our deep industry expertise within a proprietary frontier technology stack that incorporates IoT, blockchain, and AI. Our enterprise-grade solutions prioritise security, integration and interoperability, helping customers accelerate digital transformation. IQAX works with leading shipping lines, logistics providers, corporates, and financial institutions worldwide. For more information, visit www.iqax.com.

About CargoNPay

CargoNPay is a leading digital intelligent service platform in China, dedicated to digital transformation and innovative services within the international logistics industry ecosystem. Currently, the company’s many innovative products and services are at the forefront of the domestic industry, with nationwide coverage, providing users with a diverse range of comprehensive services. These include freight rate and schedule inquiries, cargo tracking, booking channels, domestic and international manifest declarations, customs declaration, insurance, AI document center services, an integrated electronic invoice system, multi-currency online payments, and supply chain finance. CargoNPay integrates internet technology, blockchain, and artificial intelligence application scenarios to connect freight forwarders, shipping companies, shipping agents, value-added service providers, banks, financial institutions, and other parties. The platform effectively addresses the pain points of traditional cross-border logistics companies — such as low efficiency, high costs, and funding bottlenecks — while also assisting industry enterprises in expanding, reducing costs, increasing efficiency, and achieving digital innovation and transformation.

SOGAGEM Expands Global Distribution Network to Drive K-Jewelry Exports

SEOUL, South Korea, Oct. 30, 2025 /PRNewswire/ — Korean fashion jewelry company SOGAGEM Co., Ltd. is accelerating its global distribution expansion, leveraging its AI and data-driven trade platform to open new export channels across Japan, the U.S., China, and Southeast Asia. The company’s strategy centers on building a next-generation global B2B ecosystem that integrates manufacturing, logistics, and digital marketing.

At the core of this initiative are SOGAGEM’s proprietary AI Jewelry Modular Designer (JMD) and Fulfillment Business Network (FBN). These systems automate product registration, recommend customized items for buyers, and connect to localized logistics services — enabling overseas partners to source Korean jewelry easily and deliver efficiently through regional fulfillment centers.

SOGAGEM has already established strategic partnerships in Japan, the U.S., and Vietnam, introducing innovative export models such as dropshipping and B2B marketplace integration. In collaboration with the Namdaemun Jewelry Association, the company also manages exclusive design IP content, offering verified product information that builds buyer trust and increases conversion rates.

CEO Moon Kyu-sik said, “SOGAGEM is more than a jewelry brand — it’s a technology-driven trade infrastructure company. By combining AI-based product matching and logistics optimization, we’re strengthening K-jewelry’s global export competitiveness.”

SOGAGEM plans to expand its fulfillment hubs across Southeast Asia and North America by 2026, while broadening its business scope beyond jewelry to beauty, fashion, and lifestyle sectors. Through these efforts, the company aims to evolve into a comprehensive AI-based digital trade ecosystem platform that connects Korean creators with the global market.